OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2023-06-30-accounts

Registered Charity Number:265985

CANCER PREVENTION RESEARCH TRUST

REPORT AND FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 JUNE 2023

CANCER PREVENTION RESEARCH TRUST

REPORT AND FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2023

CONTENTS

DESCRIPTION PAGE NO.
TRUST INFORMATION 2
TRUSTEES ANNUAL REPORT 3 – 6
INDEPENDENT EXAMINER’S REPORT 7
STATEMENT OF FINANCIAL ACTIVITIES 8
BALANCE SHEET 9
STATEMENT OF CASH FLOWS 10
NOTES TO THE ACCOUNTS 11 – 18

1

CANCER PREVENTION RESEARCH TRUST

TRUST INFORMATION FOR THE
YEAR ENDED 30 JUNE 2023
Trustees: Mr. R. O’Connor
Mr. K. Shanshol
Registered Charity Number: 265985
Place of Business: Cobden House
231 Roehampton Lane
London
SW15 4LB
Accountants: Ossmans Ltd
Chartered Accountants
591 London Road
Cheam
Sutton
Surrey
SM3 9AG
Solicitors: Russell-Cooke
7 Putney Hill
London
SW15 6AB
Bankers: NatWest
P.O. Box 13309
134 Aldersgate Street
London
EC1A 4AJ
Nationwide
95 King Street
London
W6 9JN

2

CANCER PREVENTION RESEARCH TRUST

TRUSTEES REPORT FOR THE YEAR ENDED 30 JUNE 2023

The Trustees present their report with the financial statements for the year ended 30[th ] June 2023.

Principal activities

The principal activities of the trust during the year was to raise money in order to continue with its principal objectives. These objectives are to advance medical research and, in particular, research into the prevention of cancer oncogenesis and associated malignant diseases, and to publish the results of such research.

Aims of the Trust

The objective of the Trust is to create grants for leading edge research in the UK for cancer prevention. We believe action to prevent the onset of cancer in patients before they are admitted to hospital may be more productive in reducing the spread of the disease, as opposed to investment in the use of postdiagnosis medicines.

The Trustees confirm that they have referred to the Charity Commission’s guidance on public benefit in planning future activities and objectives.

Main activities of the Trust

Performance Monitoring

Success is measured by the income generated from our present internet advertising campaign, and the outcomes of Scientific Research program conducted by Medical Research teams who have received our grants generated by advertising. We hope to keep all Trust expenditure, salaries and building maintenance less than 31%, advertising 11% and grants given out to our Cancer Research Teams to be 65% of all income.

3

CANCER PREVENTION RESEARCH TRUST

TRUSTEES REPORT FOR THE YEAR ENDED 30 JUNE 2023

Review of year

The Trust provides information to the public on cancer prevention, as well as supporting research at teaching hospitals and other establishments.

During the year the Trust received £472,548.00 in donations and legacies (2022 - £820,937.00). It provided £324,000.00 grants (2022 - £510,000.00) to universities for medical research, and in the current year, this was allocated between the following universities: University of East Anglia - £90,500, University of Manchester £140,500.00 and University of Leicester - £93,000.00.

The Trust continues to publish its Newsletter “Cancer Prevention and Health News”. The Trust advertises by use of the website https.//www.cancerpreventionresearch.co.uk/ , Lecture Note for Solicitor’s magazine, Yell on-line directory and the Newsletter.

We have recently increased our internet presence.

One of the research projects we funded has received an award in 2017 and some other projects were published and received acknowledgement in peer reviewed well respected scientific papers.

Reserves

The Trust holds reserves of £2,977,132.00 (2022 – 3,184,372.00). Of these reserves, £480,492.00 (2022 - £487,364.00) is employed in providing the Trust with property and tangible assets for the operation of the Trust’s activities. The balance of the Trust’s reserves is being accumulated for the planned construction of a Laboratory at Cobden House.

Grants Policy

We search the latest scientific papers at UK universities and offer grants support where we see key research projects relevant to a preventative approach to cancer reduction in the population. There have been three main universities benefitting from our grants, namely, East Anglia, Leicester and Manchester.

Volunteers

Presently, there are two volunteers running our local shop.

Investment Policy

The Charity operates an investment policy that carries low risk.

4

CANCER PREVENTION RESEARCH TRUST

TRUSTEES REPORT FOR THE YEAR ENDED 30 JUNE 2023

Fund Raising Policy

The principal source of income is from legacies and donations generated through on-line advertising.

The Trust is successful in raising income from internet marketing and we do expect material expenditure associated with this activity to have a positive impact on current and future fundraising.

Risks

Due to fluctuations in legacies, there could be a period in which less money is collected by the Trust. This could potentially put keeping up our payments at risk. However, to ensure the prevention of this, sufficient money is held back in reserve to meet these commitments. Furthermore, to keep a balance, we are trying to increase other means of raising funds through other forms of donations and by selling goods in our shops.

A decrease in donations and legacies we receive from the public could affect future financial performance, and thus have consequences on the fulfilment of the Charity’s objectives.

Future Plans

To consolidate our internet profile.

Make our contact with the public more interactive using Mobile phone applications on self-monitoring (looking for very early cancer signs).

The Trust plans to maintain grants awarded in future periods to meet the target of 40% of income.

The planned construction of the laboratory at Cobden House is on hold due to the construction of residential properties adjacent to the planned construction site. There are restricted funds of £1,714,443.00 at the year-end held for this purpose.

Structure, governance and management

The Charity is a registered charity, number 265985, registered with the Charities Commission. The Charity is controlled by its Trust Deed and constitutes an unincorporated charity.

Organisation Structure

The Charity makes decisions through discussions with all the Trust staff and Trustees by brainstorming sessions, and then by advice from our Legal and Financial advisors. Structural steps for decisions are: meetings with staff; legal and financial advisor meetings; minuted meetings; and then action.

5

CANCER PREVENTION RESEARCH TRUST

TRUSTEES REPORT FOR THE YEAR ENDED 30 JUNE 2023

Recruitment and Training Policy

The Trustees will internally advertise all vacant positions to current staff and volunteers to enable career advancements and increased participation. The prime trustee has the authority to appoint new trustees. The Trust aims to provide a framework for training and development that ensures staff have the necessary competencies to deliver the Trust strategy. Trustee training is achieved by access to gov.uk charity guidance and in-house workshops held by solicitors Russell-Cooke.

Trustees

No trustees are remunerated by the Trust.

Trustees’ Responsibilities

Current legislation requires Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the Trust and of the surplus or deficit for that period.

In preparing these financial statements, the trustees are required to:

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the Trust and, hence, for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Statement of disclosure of information to the Independent Examiner

So far as the trustees are aware, there is no relevant information of which the charity’s accountants are unaware and each trustee has taken all the steps that he or she ought to have as a trustee in order to make himself or herself aware of any relevant information and to establish that the Charity’s accountants are aware of that information.

The report was approved by the Board of Trustees on 15 April 2024 and signed by:

…………………………………………… …………………………………………..

Trustee Mr. R O’Connor Trustee Mr. K. Shanshol

6

CANCER PREVENTION RESEARCH TRUST

INDEPENDENT EXAMINER’S REPORT TO THE TRUSTEES YEAR ENDED 30 JUNE 2023

I report on the accounts of the Trust for the year ended 30 June 2023, which are set out on pages 8 to 10.

Respective responsibilities of Trustees and Examiner

The Charity’s trustees are responsible for the preparation of the accounts. The Charity’s trustees consider that an audit is not required for this under Section 144(2) of the Charities Act 2011 and that an independent examination is needed.

It is my responsibility to:

Basis of Independent Examiner’s Report

My examination was carried out in accordance with the general directions given by the Charity Commission. An examination includes a review of the accounting records kept by the Charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts and seeking explanations from you as trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit and, consequently, no opinion is given as to whether the accounts present a “true and fair view” and the report is limited to those matters set out in the statement below.

Independent Examiner’s Statement

In connection with my examination, no matter has come to my attention which gives me reasonable cause to believe that all material respects the requirements:

‘to keep accounting records in accordance with Section 130 of the 2011 Act, and to prepare accounts which accord with the accounting records and comply with the accounting requirements of the 2011 Act’ have been met.

Ossmans Ltd 15 April 2024 Chartered Accountants 591 London Road Cheam Sutton SM3 9AG

7

CANCER PREVENTION RESEARCH TRUST

STATEMENT OF FINANCIAL ACTIVITIES YEAR ENDED 30 JUNE 2023

Unrestricted Restricted Restricted Total Total
Funds 2023 Funds 2023 Funds 2023 Funds 2022
£ £ £ £
Income
Donations & Legacies
Donations received 125,802 - 125,802 30,184
Legacies received 346,746 - 346,746 790,753
Income from charitable activities
Sales of donated goods 3,894 - 3,894 1,450
Investment income 0 10,720 10,720 476
Rent income 8,250 0 8,250 0
Total income 484,692 10,720 495,412 822,863
Expenditure on
Fund raising and publicity (54,787) (54,787) (43,725)
Charitable activities (649,215) (649,215) (685,716)
Total Expenditure (704,002) (704,002) (729,441)
Other interest receivable and 993 - 993 6,263
other income
Net gains/(loss) on investments - 357 357
(288)
Net movement of funds (218,317) 11,077 (207,240) 99,397
Reconciliation of funds
Total funds brought forward 1,481,006 1,703,366 3,184,372 3,084,975
Net movement of funds (218,317) 11,077 (207,240) 99,397
Total funds carried forward 1,262,689 1,714,443
2,977,132		 3,184,372

All the activities of the company are from continuing operations.

8

CANCER PREVENTION RESEARCH TRUST STATEMENT OF FINANCIAL POSITION

AS AT 30 JUNE 2023

Fixed assets
Note
Tangible assets
2
Investments
3
Current assets
Debtors
4
Cash at bank and in hand
Creditors: amounts falling
due within one year
5
Total assets
Total assets less
liabilities
current
Capital and reserves
Income and expense
account
11
Total funds		 2023
£
480,492
1,816
257
2,520,318

 £
482,308

2,520,575
(25,751)
3,002,883
2,977,132
2,977,132
2,977,132		 2022
£
487,364
1,459
98
2,710,818

 £
488,823
2,710,916
(15,367)
3,199,739
3,184,372
3,184,372
3,184,372

These financial statements were approved by the board of trustees and authorized to issue on 15 April 2024, and are signed on behalf of the board by:

…………………………………………… …………………………………………..

Trustee Mr. R O’Connor Trustee Mr. K. Shanshol

9

CANCER PREVENTION RESEARCH TRUST STATEMENT OF CASH FLOW YEAR ENDED 30 JUNE 2023

Cash flows from operating activities


Cash absorbed by operations (Note 12)
Cash flows from investing activities
Purchase PPE
Dividends, interest and rents from investments
Net cash from investing activities
Net increase in cash and cash equivalents
Cash and cash equivalents at beginning of the year

Cash and cash equivalents at the end of the year

Components of cash and cash equivalents
Cash and bank balance
 2023
£

(197,693)
(3,527)
10,720
7,193
(190,500)
2,710,818
2,520,318
2,520,318
2022
£
107,968
(45,253)
476
(44,777)
63,191
2,647,627
2,710,818
2,710,818

10

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2023

1 Accounting policies

Basis of preparation

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) – Charities SORP (FRS 102) (effective 1 January 2019) and the Charities Act 2011. The accounts (financial statement) have been prepared under the historical cost convention with items recognized at cost or transaction value unless otherwise stated in the relevant note(s) to these accounts.

The Trust constitutes a public benefit entity as defined by FRS 102.

The accounts are prepared in sterling, which is the functional currency of the Charity. Monetary amounts in these financial statements are rounded to the nearest £1.

Going concern

The accounts are prepared on a going concern basis.

Income

Income is included in the Statement of Financial Activities (SoFA) when the Charity becomes entitled to, and virtually certain to receive, the income, and the amount of the income can be measured with sufficient reliability. Legacy gifts are recognized on a case by case basis following the grant of probate when the administrator/executor for the estate has communicated in writing both the amount and the settlement date. Voluntary income received by way of grants, donations and gifts is included in the SoFA when receivable and only when the Charity has unconditional entitlement to the income. The Trust recognized income from goods on sale.

Expenditure

Recognized expenditure includes any VAT which cannot be fully recovered, and is reported as part of the expenditure to which it relates. Expenditure on raising funds comprise the cost associate with attracting voluntary income fundraising cost and investment management costs. Expenditure on charitable activities comprise the cost incurred by the Charity in the delivery of its activities and services in the furtherance of its objectives, including the making of grants and governance costs.

11

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

1 Accounting Policies (continued)

Expenditure (continued)

Governance costs include those costs associated with meeting the constitutional and statutory requirements of the Charity, including the independent examination fees, costs linked to the strategic management of the Charity, together with the share of other administration costs.

Grants payable are payments made to third parties in the furtherance of the charitable objectives of the Trust. In case of an unconditional grant offer, this is accrued once the recipient has been notified of the grant award. Provisions for grants are made when the intention to make a grant has been communicated to the grant recipient but there is uncertainty as to the meeting of the grant terms.

Taxation

The Charity is exempt from tax on its charitable activities.

Depreciation

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life:

Plant and machinery 25% on reducing balance basis

Furniture and equipment 25% on reducing balance basis Motor van 25% on reducing balance basis

Depreciation charge in the year of acquisition and not in the year of disposal.

The Trustees are of the opinion that no depreciation is charged on the freehold properties.

Debtors

Prepayments are valued at the amount prepaid net of any trade discounts due.

Cash and cash equivalents

Cash and cash equivalents comprise at bank and in hand, demand deposits with banks and other shortterm highly liquid investments, with original maturities of three months or less, and bank overdrafts. In the statement of financial position, bank overdrafts are shown within creditors. In the Statement of Cash Flows, cash and cash equivalents are shown net of bank overdrafts that are repayable on demand and form an integral part of the trust cash management.

12

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

1 Accounting Policies (continued)

Creditors and provisions

Creditors and provisions are recognized where the charity has obligations resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognized at their settlement amount after allowing for any trade discounts due.

Investments policy

Investments are a form of basic financial instrument and are initially recognized at their transaction value and subsequently measured at their fair value as at their balance sheet date using the closing quoted market price. The statement of financial activities includes the net gains and losses arising on revaluation and disposals throughout the year.

Realized gains and losses

All gains and losses are taken to the Statement of Financial Activities as they arise. Realized gains and losses on investments are calculated as the difference between sales proceeds and their opening carrying value or their purchase value if acquired subsequent to the first day of the financial year. Unrealized gains and losses are calculated as the difference between the fair value at the year end and their carrying value. Realized and unrealized investment gains and losses are combined in the Statement of Financial Activities.

Pension Costs

The Charity operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the charity pays fixed contributions into a separate entity. Once the contributions have been paid the charity has no further payments obligations. The contributions are recognized as expenses when they fall due. Amounts not paid are shown in accruals in the balance sheet. The assets of the plan are held separately from the charity in independently administered funds.

Funds

Restricted funds are funds which are to be used in accordance with specifications imposed by the donor or trust deed. There is a single restricted fund (Cobden House Fund) earmarked for the construction of the Laboratory at Cobden House.

Unrestricted income funds comprise those funds which the trustees are free to use for any purpose in furtherance of the charitable objectives. Unrestricted funds include designated funds where the trustees, at their discretion, have created a fund for a specific purpose.

13

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

2
Tangible assets
Cost
At 1 July 2022
Additions
At 30 June 2023
Depreciation
At 1 July 2022
Charge for the year
At 30 June 2023
Carrying amount
At 30 June 2023
At 30 June 2022
3
INVESTMENTS
Cost
At 1 July 2022
Fair value adjustment
At 30 June 2022
Impairment
At 1 July 2023 and30 June 2023
Carrying amount
At 30 June 2023
At 30 June 2022		 Freehold
property
£
449,294
449,294
-
-
-
449,294
449,294		 Plant and
machinery
Motor vehicle
Fixtures,
fittings and
equipment
Total
£
£
£
£
72,270
42,002
28,804
592,370
3,285
242
3,527
75,555
42,002
29,046
595,897
66,144
10,501
28,361
105,006
2,353
7,875
171
10,399
68,497
18,376
28,532
115,405
7,058
23,626
514
480,492
6,126
31,501
443
487,364
Ordinary shares at listed
investments at market
value
£
Total
£
1,459
1,459
357
357
1,816
1,816
-
-
1,816
1,816
1,459
1,459		 Total
£
592,370
3,527
595,897
105,006
10,399
115,405
480,492
487,364

14

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

4
DEBTORS

Other debtors
Prepayments
5
CREDITORS
Amounts falling due within one year
Rent advance
Social security and other taxes
Other creditors
6
ANALYSIS OF CHARITABLE EXPENDITURE

Staff costs
Grants awards
Vehicles expenses
Property expenses
Insurance
Credit card charges
Depreciation
Loss on disposal
Other costs
Legal and professional
Accountancy fees		 2023
£
-
257
257
2023
£
8,250
3,334

14,167
25,751
2023
£

135,184
324,000
8,342
151,756
5,317

-

10,399

-
3,627
5,190
5,400
649,215		 2022
£
-
98
98
2022
£
-
-
15,367
15,367
2022
£
126,645
510,000
2,255
24,778
1,145
-
12,690
-
2,388
415
5,400
685,716

7 ANALYSIS OF GRANTS

In the year, the following grants were made to institutions for medical research:



University of East Anglia

University of Manchester
University of Leicester		 2023

£
90,500

140,500

93,000

324,000
 2022
£
170,000
140,000
200,000
510,000

15

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

8 ANALYSIS OF STAFF COST AND REMUNERATION


Salaries and wages

Social security costs
Other pension cost
 2023

£

112,000

12,024

11,160

135,184		 2022
£
104,500
10,985
11,160
126,645

The average number of employees during the year 2023 - 3 (2022 – 3) with all employees providing either support to the governance of the Charity, or support services to charitable activities. No employees received total employee benefits of more than £60,000.00.

9 RELATED PARTY

No remuneration was paid to the trustees in the year 2023 (2022 - Nil).

10 ANALYSIS OF NET ASSETS BETWEEN FUNDS

Current year
Unrestricted
funds
£
Restricted funds
£
Fixed assets
480,492
1,816
Net current assets
782,197
1,712,627
Long term liabilities
0
0
1,262,689
1,714,443
Prior year
Fixed assets
487,364
1,459
Net current assets
993,642
1,701,907
Long term liabilities
0
0
1,481,006
1,703,366		 Total
£
482,308
2,494,824
0
2,977,132
488,823
2,695,549
0
3,184,372

Restricted funds are made up of the Cobden House Fund earmarked for the construction of the Laboratory at Cobden House.

16

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

11 ANALYSIS OF MOVEMENTS IN FUNDS

Current year
Unrestricted funds

Restricted funds
Cobden House fund

Prior yield

Unrestricted funds
Restricted funds
Cobden House Fund		 Balance
1.7.2022
£
1,481,006
1,703,366
3,184,372


Balance
1.7.2021
£
1,381,797

1,703,178
3,084,975

 Income
£
484,692
Expenditure
£
(704,002)
Gains/losses
£
993
10,720
494,212
(704,002)
357
1,350
Income
£
Expenditure
£
Gains/losses
£
822,387
(729,441)
6,263
476
822,863
-
(729,441)
(288)
5,975		 Balance
30.6.2023
£
1,262,689
1,714,443
2,977,132
Balance
30.6.2022
£
1,481,006
1,703,366
3,184,372


12
CASH GENERATED FROM OPERATIONS
Cash flows from operating activities
Profit/(loss) for the financial year
Adjustments for:
Depreciation
Loss on disposal
Investment income
Gain/(loss) on investment
Interest income
Movement in working capital:
(Increase)/decrease in debtors
Increase/(decrease) in creditors

Net cash used operating activities		 2023
£
(207,240)

10,399
-
(10,720)
(357)
(159)

10,384
(197,693)
 2022
£
99,397
12,690
(476)
288
378
(4,309)
107,968

17

CANCER PREVENTION RESEARCH TRUST

STATEMENT OF FINANCIAL STATEMENTS YEAR ENDED 30 JUNE 2023



INCOME
Donations

Legacies

Sales of donated goods

Interest received

Rent income

Dividends received


Other income


EXPENDITURE
Staff salaries and pensions

Grants

Advertising

Printing, postage and stationery

Light and heat

Telephone and Internet

Rates and Water

Legal and Professional

Accountancy
Service charges
Repairs and maintenance, Renewals

Insurance
Cleaning

Computer and equipment costs

Book publications and subscriptions
Bank charges and interest

Sundries

Hire of equipment
Subscriptions


Motor expense
Loss on revaluation of investments

Gain on revaluation of investments
Lease
Depreciation of tangible assets

Excess of income over expenditure
 2023
£


125,802

346,746

3,894
10,720
8250
0
495,412
993

496,405

135,184
324,000
54,787
230
2,285
3,560
6,122
5,190

5,400
0
131,400
5,317

6,031
2,130
0

412

759

0
2,454

8,342
0
(357)
-
10,399
703,645
(207,240)
 2022
£
30,184
790,753
1,450
476
0
0
822,863
6,26~~3~~
829,126
126,645
510,000
43,725
730
3,504
2,532
7,484
415
5,400
0
4,437
1,145
2,119
1,468
906
135
816
2,503
531
2,256
288
-
-
12,690
729,729
99,397		 2022
£
30,184
790,753
1,450
476
0
0
822,863
6,26~~3~~
829,126
126,645
510,000
43,725
730
3,504
2,532
7,484
415
5,400
0
4,437
1,145
2,119
1,468
906
135
816
2,503
531
2,256
288
-
-
12,690
729,729
99,397		 2022
£
30,184
790,753
1,450
476
0
0
822,863
6,26~~3~~
829,126
126,645
510,000
43,725
730
3,504
2,532
7,484
415
5,400
0
4,437
1,145
2,119
1,468
906
135
816
2,503
531
2,256
288
-
-
12,690
729,729
99,397
99,397

18

CANCER PREVENTION RESEARCH TRUST

NOTES TO THE FINANCIAL STATEMENTS (continued) YEAR ENDED 30 JUNE 2023

19